on B.R.A.I.N. Biotechnology Research And Information Network AG (isin : DE0005203947)
BRAIN Biotech AG Announces Erik de Vries as Senior Business Development Director
BRAIN Biotech AG has appointed Dr. Erik de Vries as the new Senior Business Development Director Enzymes, effective June 1, 2024. De Vries will balance this role while maintaining his position as CEO of Enzymicals AG part-time until the end of the year.
A succession plan is in place, with a new CEO for Enzymicals AG starting on January 1, 2025. De Vries is expected to join Enzymicals’ Supervisory Board at the Annual General Meeting in 2025, continuing to support the company's growth strategy.
Prof. Dr. Uwe Bornscheuer, Chairman of Enzymicals AG's Supervisory Board, expressed confidence in De Vries' contributions, highlighting record revenues and new project successes under his leadership.
Dr. Martin Langer of BRAIN Biotech AG praised De Vries' expertise, noting the synergy potential between BRAIN Biotech and Enzymicals. De Vries aims to leverage his deep market insights to boost revenues and foster collaborations between the two companies.
R. H.Copyright © 2024 FinanzWire, all reproduction and representation rights reserved. Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all B.R.A.I.N. Biotechnology Research And Information Network AG news